Get to know our clinical trials
Trial of HFB200603 (anti-BTLA antibody) in monotherapy and in combination with tislelizumab (anti-PD-1 antibody) in adult patients with advanced solid tumors.
THE PURPOSE OF THIS RESEARCH STUDY IS TO: &IQUEST; DETERMINE THE SAFETY AND TOLERABILITY OF HFB200603 AT DIFFERENT DOSES, IN MONOTHERAPY AND IN COMBINATION WITH TISLELIZUMAB. DOSE&IQUEST; IS DEFINED AS THE AMOUNT OF STUDY DRUG YOU RECEIVE, SUCH AS 50 MG. &IQUEST; DETERMINE THE HIGHEST DOSE OF HFB200603 THAT CAN BE GIVEN TO PARTICIPANTS WITHOUT CAUSING THEM TOO SEVERE SIDE EFFECTS AND/OR DISCOMFORT, WHEN GIVEN IN MONOTHERAPY AND IN COMBINATION WITH TISLELIZUMAB. DETERMINE WHAT HFB200603 DOES IN YOUR BODY (KNOWN AS PHARMACODYNAMICS, OR PD) AND WHAT YOUR BODY DOES WITH THE STUDY DRUG (KNOWN AS PHARMACOKINETICS, OR PK) WHEN GIVEN ALONE AND IN COMBINATION WITH TISLELIZUMAB. DETERMINE WHETHER HFB200603 ALONE AND IN COMBINATION WITH TISLELIZUMAB IS EFFECTIVE IN TREATING YOUR CANCER. DETERMINE HOW HFB200603 ALONE AND IN COMBINATION WITH TISLELIZUMAB AFFECT YOUR IMMUNE SYSTEM.
- PHASE 1A/1B, OPEN-LABEL, MULTICENTER, MULTICENTER, STEPWISE DOSE ESCALATION AND DOSE ESCALATION STUDY OF HFB200603 (ANTI-BTLA ANTIBODY) IN MONOTHERAPY AND IN COMBINATION WITH TISLELIZUMAB (ANTI-PD-1 ANTIBODY) IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS.
- Code EudraCT: 2022-502891-22
- Protocol number: HFB-200603-01
- Promoter: HiFiBiO Inc.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.